Gyre Pharmaceuticals Co., Ltd.(also known as Beijing Continent Pharmaceuticals Co., Ltd.) was founded in 2002, which is a innovate drug development enterprise committed to organ fibrosis diseases, and integrated R&D, production and commercialization. Gyre Pharmaceuticals is the holding subsidiary of the NASDAQ-listed company Gyre Therapeutics, Inc. (Stock Ticker: GYRE).
As a pioneer in the field of anti-organ fibrosis, company's flagship product Class 1.1 new drug ETUARY? (Pirfenidone Capsule) is one of the only two types approved drugs for IPF treatment worldwide. As the first innovate drug approved to be used for IPF in China, it filled the gap in the IPF treatment field after its successful launch in 2014. F351 (Hydronidone) the company's key production for next stage, was granted a Breakthrough Therapy designation as the liver fibrosis treatment drug by the CDE. It is expected to be the first approved?chemical?drug for the treatment of liver fibrosis associated with CHB.
The company will enrich and boost the product pipeline by utilizing our successful and complete experience accumulated from in-house development to commercialization of ETUARY?. We are expanding our therapeutic field to other organs fibrosis by researching and developing the treatment of pulmonary fibrosis, liver fibrosis and renal fibrosis to bring new hope to the patients with organs fibrosis.
© 2011 - 2026 Gyre Pharmaceuticals All Rights Reserved. 京ICP備17017473號-3
藥品醫療器械網絡信息服務備案: (京)網藥械信息備字(2025)第00291號